Acromegaly Treatment Market Cover Image

Global Acromegaly Treatment Market By Product (Somatostatin Analogs, Growth Hormone Receptor Antagonist (GHRA), and Dopamine Agonist), By End User (Hospitals & Clinics, and Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa)

  • Report ID: HC-17
  • Author: Growth Market Reports
  • Rating: 4.2
  • Total Reviews: 76
  • No. Of Pages: 166
  • Format:
  • Pub. Date: 2020-08-03
  • Share:

Market Outlook:

The global acromegaly treatment market was valued at USD 1,304.4 Million in 2019 and is projected to reach USD 2,299.4 Million by 2027, expanding at a CAGR of 7.6% during the forecast period. Acromegaly is rare acquired endocrine disease which is related to excessive production of growth hormone (GH) and it is characterized by progressive systemic manifestation and somatic disfigurement (it involves the extremities and face).
 

Acromegaly Treatment Market Executive Summary

Market Dynamics

The market is driven by factors such as rising prevalence of acromegaly, growing number of hormonal diseases, rising number of clinical trials, and increasing awareness among people for acromegaly. Conversely, high cost for treatment and lack of awareness and infrastructure in under developed countries are acting as key restraints of this market. Untapped opportunities in emerging countries and rising investment in research and development are expected to create opportunities for market in the future.

Segmental Outlook

On the basis of products, the acromegaly treatment market is divided into somatostatin analogs, growth hormone receptor antagonist (GHRA), and dopamine agonist. The somatostatin analogs are anticipated to expand at a CAGR of 7.9% during the forecast period due to the wide availability of drugs and cost efficiency. The growth hormone receptor antagonist segment is estimated to hold around 1/5th share of the market in 2020 owing to the inclusion of genetically engineered growth hormone which is used for blocking the dimerization of GH receptor.
 

Acromegaly Treatment Market Analysis By Product

Based on end-users, the market is segmented into hospitals & clinics, and others. Hospital & clinics is projected to be attractive segment during the forecast period. Hospital & clinics are preferred by patients, as they provide medical and diagnostic treatments.

Definitions

By Product

Acromegaly Treatment Market BPS Analysis

Somatostatin Analogs: Somatostatin analogs are drugs that are used for stopping the excessive hormone secretion in the human body. Acromegaly and neuroendocrine tumor (NET) is a rare hormonal disorder, which is commonly treated with somatostatins analogs. Other types of common tumors that are treated with somatostatin analogs are GH-secreting tumors, VIPomas, glucagonomas, and carcinoid tumors. Somatostatins analogs are also used for treating Cushing syndrome. Somatostatins analogs is a synthetic version of somatostatins, which helps slow down the production of hormones of serotonins and growth hormones. Somatostatin analogs help control the symptoms of carcinoid syndromes such as flushing of the skin and diarrhea.

Growth Hormone Receptors Antagonists (GHRA): The growth hormone is produced by the pituitary gland that regulates growth in children and affects fat, sugar, protein breakdown in adults and children. Excess levels of growth hormone can cause gigantism in adolescents & children and acromegaly in adults. Growth hormone receptors antagonists are used for the treatment of acromegaly to protect people from hormone diseases. They are used for blocking the growth of hormones in the body, as it helps reduce excess tissue growth. In the human body, GHRA is given in the form of subcutaneous injection, which helps reduce the production of insulin-like growth factor (IGF -1) by the liver. Currently, there is only one type of growth hormone receptor antagonist present in the market.

Dopamine Agonist: Dopamine agonist is a prescribed medication, which is used in the combination with other medicines or alone to treat a variety of conditions that are resulted from dopamine loss. It is has been found that dopamine receptors are responsible for many muscle-, hormone-, and behavior-related effects in the body. Dopamine agonist drugs have mostly been prescribed to the patient who suffer from hormone- and movement-related disorders. This drug helps reduce the release of growth hormone in the human body.

By End User

Hospital & Clinic: A hospital & clinic is a health care facility that provides patients with specialist medical service and medical facilities. Hospitals are categorized as general, specialty, or government, depending on the source of income earned. A general hospital is the most well-known type of hospital. It usually has an emergency ward to cater to urgent health problems ranging from burn and accident victims to a sudden illness. A district hospital is a healthcare facility having multiple beds for intensive care and additional beds for patients in need of long-term care. Hospitals have a number of departments (including surgery and emergency care) and specialist facilities including cardiology. A clinic (or medical clinic or hospital clinic) is a health-care facility mainly for the treatment of the outpatient. Clinics cover the primary healthcare needs of the population in local communities by providing specialized treatments and admitting patients for overnight stays.

Others: Government organizations play an important role in the improvement of the health of people through strengthening the health system and providing health care facilities to all the people in their country. Government organization needs to achieve their goals by improving health condition, securing equity in health care financing, and reducing health inequalities.

The main task of private organizations in the health system is to provide health advocacy and services to the unprivileged people. Moreover, they need to provide social, psychological services, integration activities, nursing and care, financial and medical support, information services, and training.

Regional Outlook

In terms of regions, the global acromegaly treatment market is fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is a promising region for the market. The region constituted 1/5 of the market in 2020. The market in the region is projected to expand at a CAGR of 8.0% during the forecast period. Rising awareness regarding hormone-related diseases and rising healthcare expenditure are driving the acromegaly treatment market in Asia Pacific. The market in North America is projected to expand at a CAGR of 7.5% due growing prevalence of acromegaly in the region. According, to the American Society of Clinical Oncology (ASCO) in the US, 14,230 people were diagnosed with pituitary gland tumor in 2017.

Acromegaly Treatment Market Size By Country

Competitive Landscape

  • Key players in the global acromegaly treatment market includes Novartis AG, Sun Pharmaceutical Industries Ltd., DAEWOONG PHARMACEUTICAL CO.,LTD., Dauntless Pharmaceuticals, and WOCKHARDT. These companies are considered as key manufacturers of acromegaly treatment drugs, based on their revenue, research & development activities, regional presence, and supply chain management system.

  • The players are adopting key strategies such as acquisition, and geographical expansion where potential opportunity for the Acromegaly Treatment extraction is added in the company’s capacity.

  • For instance, In June 2020, Chiasma Inc announced that its MYCAPSSA (Octreotide) capsules, which is the first and only oral somatostatin analog, received FDA approval.

  • In October 2019, Sun Pharmaceutical Industries Ltd. launched Drizalma Sprinkle (duloxetine delayed-release capsules) in the US for oral use. The Drizalma Sprinkle (duloxetine delayed-release capsules) is designed for the treatment of various neuro-psychiatric and pain disorders in patients who have difficulty in swallowing.

  • In April 2019, Ipsen Pharma completed acquisition of Clementia Pharmaceuticals. This acquisition provided clear validation of strategy and bolstered rare diseases pipeline with a strong cornerstone asset for multiple indications.

Acromegaly Treatment Market Share Analysis


Key Benefits for Industry Participants & Stakeholders

  • In-depth Analysis of the Global Acromegaly Treatment Market

  • Historical, Current and Projected Market Size in terms of Value

  • Potential & Niche Segments and Regions Exhibiting Promising Growth Covered

  • Industry Drivers, Restraints and Opportunities Covered in the Study

  • Recent Industry Trends and Developments

  • Competitive Landscape & Strategies of Key Players

  • Neutral Perspective on Global Acromegaly Treatment Market Performance

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Acromegaly Treatment Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Acromegaly Treatment Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Acromegaly Treatment Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Acromegaly Treatment Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Acromegaly Treatment Market Size & Forecast, 2017-2027
      4.5.1 Acromegaly Treatment Market Size and Y-o-Y Growth
      4.5.2 Acromegaly Treatment Market Absolute $ Opportunity
   4.6 Regulatory & Political Forces
   4.7 Acromegaly Treatment market - SWOT Analysis
   4.8 Acromegaly Treatment market By Factor (Political & Legal, Economic And Technological)

Chapter 5 Global Acromegaly Treatment Market Analysis and Forecast By Product
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Product
      5.1.2 Basis Point Share (BPS) Analysis By Product
      5.1.3 Absolute $ Opportunity Assessment By Product
   5.2 Acromegaly Treatment Market Size Forecast By Product
      5.2.1 Somatostatin Analogs
      5.2.2 Growth Hormone Receptors Antagonists (GHRA)
      5.2.3 Dopamine Agonist
   5.3 Market Attractiveness Analysis By Product
Chapter 6 Global Acromegaly Treatment Market Analysis and Forecast By End-user
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By End-user
      6.1.2 Basis Point Share (BPS) Analysis By End-user
      6.1.3 Absolute $ Opportunity Assessment By End-user
   6.2 Acromegaly Treatment Market Size Forecast By End-user
      6.2.1 Hospital & Clinic
      6.2.2 Others
   6.3 Market Attractiveness Analysis By End-user
Chapter 7 Global Acromegaly Treatment Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Acromegaly Treatment Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 North America Acromegaly Treatment Analysis and Forecast
   8.1 Introduction
   8.2 North America Acromegaly Treatment Market Size Forecast by Country
      8.2.1 U.S.
      8.2.2 Canada
   8.3 Basis Point Share (BPS) Analysis by Country
   8.4 Absolute $ Opportunity Assessment by Country
   8.5 Market Attractiveness Analysis by Country
   8.6 North America Acromegaly Treatment Market Size Forecast By Product
      8.6.1 Somatostatin Analogs
      8.6.2 Growth Hormone Receptors Antagonists (GHRA)
      8.6.3 Dopamine Agonist
   8.7 Basis Point Share (BPS) Analysis By Product
   8.8 Absolute $ Opportunity Assessment By Product
   8.9 Market Attractiveness Analysis By Product
   8.10 North America Acromegaly Treatment Market Size Forecast By End-user
      8.10.1 Hospital & Clinic
      8.10.2 Others
   8.11 Basis Point Share (BPS) Analysis By End-user
   8.12 Absolute $ Opportunity Assessment By End-user
   8.13 Market Attractiveness Analysis By End-user
Chapter 9 Europe Acromegaly Treatment Analysis and Forecast
   9.1 Introduction
   9.2 Europe Acromegaly Treatment Market Size Forecast by Country
      9.2.1 Germany
      9.2.2 France
      9.2.3 Italy
      9.2.4 U.K.
      9.2.5 Spain
      9.2.6 Russia
      9.2.7 Rest of Europe
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 Europe Acromegaly Treatment Market Size Forecast By Product
      9.6.1 Somatostatin Analogs
      9.6.2 Growth Hormone Receptors Antagonists (GHRA)
      9.6.3 Dopamine Agonist
   9.7 Basis Point Share (BPS) Analysis By Product
   9.8 Absolute $ Opportunity Assessment By Product
   9.9 Market Attractiveness Analysis By Product
   9.10 Europe Acromegaly Treatment Market Size Forecast By End-user
      9.10.1 Hospital & Clinic
      9.10.2 Others
   9.11 Basis Point Share (BPS) Analysis By End-user
   9.12 Absolute $ Opportunity Assessment By End-user
   9.13 Market Attractiveness Analysis By End-user
Chapter 10 Asia Pacific Acromegaly Treatment Analysis and Forecast
   10.1 Introduction
   10.2 Asia Pacific Acromegaly Treatment Market Size Forecast by Country
      10.2.1 China
      10.2.2 Japan
      10.2.3 South Korea
      10.2.4 India
      10.2.5 Australia
      10.2.6 South East Asia (SEA)
      10.2.7 Rest of Asia Pacific (APAC)
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Asia Pacific Acromegaly Treatment Market Size Forecast By Product
      10.6.1 Somatostatin Analogs
      10.6.2 Growth Hormone Receptors Antagonists (GHRA)
      10.6.3 Dopamine Agonist
   10.7 Basis Point Share (BPS) Analysis By Product
   10.8 Absolute $ Opportunity Assessment By Product
   10.9 Market Attractiveness Analysis By Product
   10.10 Asia Pacific Acromegaly Treatment Market Size Forecast By End-user
      10.10.1 Hospital & Clinic
      10.10.2 Others
   10.11 Basis Point Share (BPS) Analysis By End-user
   10.12 Absolute $ Opportunity Assessment By End-user
   10.13 Market Attractiveness Analysis By End-user
Chapter 11 Latin America Acromegaly Treatment Analysis and Forecast
   11.1 Introduction
   11.2 Latin America Acromegaly Treatment Market Size Forecast by Country
      11.2.1 Brazil
      11.2.2 Mexico
      11.2.3 Rest of Latin America (LATAM)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Latin America Acromegaly Treatment Market Size Forecast By Product
      11.6.1 Somatostatin Analogs
      11.6.2 Growth Hormone Receptors Antagonists (GHRA)
      11.6.3 Dopamine Agonist
   11.7 Basis Point Share (BPS) Analysis By Product
   11.8 Absolute $ Opportunity Assessment By Product
   11.9 Market Attractiveness Analysis By Product
   11.10 Latin America Acromegaly Treatment Market Size Forecast By End-user
      11.10.1 Hospital & Clinic
      11.10.2 Others
   11.11 Basis Point Share (BPS) Analysis By End-user
   11.12 Absolute $ Opportunity Assessment By End-user
   11.13 Market Attractiveness Analysis By End-user
Chapter 12 Middle East & Africa (MEA) Acromegaly Treatment Analysis and Forecast
   12.1 Introduction
   12.2 Middle East & Africa (MEA) Acromegaly Treatment Market Size Forecast by Country
      12.2.1 Saudi Arabia
      12.2.2 South Africa
      12.2.3 UAE
      12.2.4 Rest of Middle East & Africa (MEA)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Middle East & Africa (MEA) Acromegaly Treatment Market Size Forecast By Product
      12.6.1 Somatostatin Analogs
      12.6.2 Growth Hormone Receptors Antagonists (GHRA)
      12.6.3 Dopamine Agonist
   12.7 Basis Point Share (BPS) Analysis By Product
   12.8 Absolute $ Opportunity Assessment By Product
   12.9 Market Attractiveness Analysis By Product
   12.10 Middle East & Africa (MEA) Acromegaly Treatment Market Size Forecast By End-user
      12.10.1 Hospital & Clinic
      12.10.2 Others
   12.11 Basis Point Share (BPS) Analysis By End-user
   12.12 Absolute $ Opportunity Assessment By End-user
   12.13 Market Attractiveness Analysis By End-user
Chapter 13 Competition Landscape
   13.1 Acromegaly Treatment Market: Competitive Dashboard
   13.2 Global Acromegaly Treatment Market: Market Share Analysis, 2019
   13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
      13.3.1 Amryt Pharma plc
      13.3.2 Aquestive Therapeutics, Inc.
      13.3.3 Chiasma Inc
      13.3.4 Daewong Pharmaceuticals Co Ltd.
      13.3.5 Dauntless Pharmaceuticals 
      13.3.6 Foresee Pharmaceuticals LLC
      13.3.7 Glide Pharmaceuticals Ltd
      13.3.8 Ionis Pharmaceuticals
      13.3.9 Ipsen Pharma
      13.3.10 Novartis AG
      13.3.11 Peptron
      13.3.12 Pfizer Inc.
      13.3.13 Strongbridge Biopharma plc
      13.3.14 Sun Pharmaceutical Industries Ltd
      13.3.15 WOCKHARDT
Key Segments Covered
By Product
  • Somatostatin Analogs
  • Growth Hormone Receptors Antagonists (GHRA)
  • Dopamine Agonist
By End User
  • Hospitals & Clinics
  • Others
By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific (APAC)
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • South Africa
    • UAE
    • Rest of Middle East & Africa (MEA)
Key Market Players Profiled in the Report
  • Amryt Pharma plc
  • Aquestive Therapeutics, Inc.
  • Chiasma Inc
  • Daewong Pharmaceuticals Co Ltd.
  • Dauntless Pharmaceuticals 
  • Foresee Pharmaceuticals LLC
  • Glide Pharmaceuticals Ltd
  • Ionis Pharmaceuticals
  • Ipsen Pharma
  • Novartis AG
  • Peptron 
  • Pfizer Inc.
  • Strongbridge Biopharma plc
  • Sun Pharmaceutical Industries Ltd
  • WOCKHARDT

Buy Report

FAQ Section

Some frequently asked quetions about this report!

Additional company profiles can be provided on request.

Yes, the report covers product specific information such as composition development etc.

According to this Growth Market Reports report, the market from Acromegaly Treatment is likely to register a CAGR of 7.6% during forecast period 2020-2027, with an anticipated to reach USD 2,299.4 million by the end of the 2027.

In addition Regulations and Company Market Share (in % for base year 2019), SWOT analysis of the market, Political & Legal, Economic and Technological analysis for Acromegaly Treatment market is available in final report.

Rising prevalence of acromegaly, growing number of hormonal diseases, rising number of clinical trials, and increasing awareness among people for acromegaly.

Hospitals & Clinics and Others are the key end-user that are driving the Acromegaly Treatment market.

Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.

The market is expected to maintain its normal growth between 2019 and 2020 owing to the continuous supply medicine and acromegaly cases. The ongoing research on acromegaly drug is expected to grow the demand for acromegaly treatment in the market.

The base year considered for the global Acromegaly Treatment market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027.

Major manufactures include, Novartis AG, Sun Pharmaceutical Industries Ltd., DAEWOONG PHARMACEUTICAL CO., LTD., Dauntless Pharmaceuticals, WOCKHARDT.